Table 5.
All concomitant drugs and concomitant antidiabetic drugs received by FG patients under SGLT2 inhibitor therapy.
| All concomitant drugs | n (%) | Concomitant antidiabetic drugs | n (%) |
|---|---|---|---|
| Cardiovascular system | 355 (34.84%) | Metformin | 110 (34.81%) |
| Endocrine system | 329 (32.29%) | Insulin | 98 (31.01%) |
| Nervous system | 61 (5.99%) | Dipeptidyl peptidase-4 inhibitors | 54 (17.09%) |
| Gastrointestinal system | 60 (5.89%) | Sulfonylurea | 37 (11.71%) |
| Blood and nutrition | 48 (4.71%) | Thiazolidinediones | 8 (2.53%) |
| Anti-inflammatory and analgesic | 36 (3.53%) | Combination therapy | 5 (1.58%) |
| Respiratory system | 29 (2.85%) | Meglitinides | 2 (0.63%) |
| Infection | 22 (2.16%) | Alpha-glucosidase inhibitors | 1 (0.32%) |
| Immune system and malignant disease | 21 (2.06%) | Other | 1 (0.32%) |
| Controlled drug | 18 (1.77%) | Total | 316 |
| Genitourinary system | 18 (1.77%) | ||
| Others | 17 (1.67%) | ||
| Skin | 4 (0.39%) | ||
| Musculoskeletal system | 1 (0.10%) | ||
| Total | 1019 |